The paper's citation list
No.The paper's citation list
1Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. 2020;16:62 doi: 10.2174/1573394715666190913184853
2Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8
3Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation. 2020;33:469 doi: 10.1007/s10334-019-00817-4
4Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease. 2020;12:1649 doi: 10.3390/cancers12061649
5Immunotherapy. 2020;1244:255 doi: 10.1007/978-3-030-41008-7_13
6Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2020;6:29 doi: 10.1007/s40883-019-00113-6
7Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. 2020;12:432 doi: 10.3390/cancers12020432
8. 2020; doi: 10.1007/5584_2020_522
9Reference Module in Biomedical Sciences. 2020; doi: 10.1016/B978-0-12-801238-3.11605-8
10Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT-CRP Induces Selective ROS-Dependent Apoptosis in T-Acute Lymphoblastic Leukemia Cell Lines. 2020;2020:1 doi: 10.1155/2020/1598503
11The emergence of drug resistance to targeted cancer therapies: Clinical evidence. 2019;47:100646 doi: 10.1016/j.drup.2019.100646
12Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6
13Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50: doi: 10.1038/s12276-018-0115-0
14Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139
15Principles of Tumors. 2020;453 doi: 10.1016/B978-0-12-816920-9.00018-3
16CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105
17Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877
18MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019
19Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433
20Peptide-based targeting of immunosuppressive cells in cancer. 2020;5:92 doi: 10.1016/j.bioactmat.2020.01.006
21Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. 2020;1 doi: 10.1080/08820139.2020.1748047
22Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. 2020;106:104722 doi: 10.1016/j.oraloncology.2020.104722
23Editorial. 2019;12:3 doi: 10.1111/ors.12402
24Active immunotherapy of cancer: An overview of therapeutic vaccines. 2019;69:490 doi: 10.5937/arhfarm1906490F
25Combined strategies for tumor immunotherapy with nanoparticles. 2019;21:1441 doi: 10.1007/s12094-019-02081-3
26Biomaterials for Cancer Therapeutics. 2020;331 doi: 10.1016/B978-0-08-102983-1.00012-0
27Modeling immune cell behavior across scales in cancer. 2020;12:e1484 doi: 10.1002/wsbm.1484
28Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. 2019;11:248 doi: 10.1007/s12609-019-00332-4
29Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396
30Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. 2020;37:354 doi: 10.1016/j.ccell.2020.02.001
31Immunotherapy and other systemic therapies for cutaneous SCC. 2019;99:104459 doi: 10.1016/j.oraloncology.2019.104459
32Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. 2020;7:7 doi: 10.2217/mmt-2019-0020
33O-acetylated Gangliosides as Targets for Cancer Immunotherapy. 2020;9:741 doi: 10.3390/cells9030741
34Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. 2020;20: doi: 10.1186/s12874-020-00997-x
35Cancer and the Immune System: The History and Background of Immunotherapy. 2019;35:150923 doi: 10.1016/j.soncn.2019.08.002
36The need for rapid therapeutic efficacy testing for cancer therapy. 2020;113:104382 doi: 10.1016/j.yexmp.2020.104382
37Integrative Nanomedicine for New Therapies. 2020;321 doi: 10.1007/978-3-030-36260-7_12
38Emerging therapeutic agents for advanced non-small cell lung cancer. 2020;13: doi: 10.1186/s13045-020-00881-7
39The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. 2020;10:666 doi: 10.3390/biom10050666
40Molecular and Cell Biology of Cancer. 2019;117 doi: 10.1007/978-3-030-11812-9_7
41Novel therapeutic strategies for spinal osteosarcomas. 2020;64:83 doi: 10.1016/j.semcancer.2019.05.018
42Current Applications for Overcoming Resistance to Targeted Therapies. 2019;20:97 doi: 10.1007/978-3-030-21477-7_4
43Cancer: The Enemy from Within. 2020;223 doi: 10.1007/978-3-030-40651-6_9
44Learning-accelerated discovery of immune-tumour interactions. 2019;4:747 doi: 10.1039/C9ME00036D
45Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. 2020;112:562 doi: 10.1093/jnci/djaa021
46The Microbiome in Health and Disease. 2020;171:301 doi: 10.1016/bs.pmbts.2020.04.004
47Resistance to Targeted Therapies in Lymphomas. 2019;21:155 doi: 10.1007/978-3-030-24424-8_7
48A guide to cancer immunotherapy: from T cell basic science to clinical practice. 2020; doi: 10.1038/s41577-020-0306-5
49CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. 2020;19:191 doi: 10.1093/bfgp/elz039
50Current trends in cancer immunotherapy: a literature-mining analysis. 2020; doi: 10.1007/s00262-020-02630-8
51Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. 2019;19:2158 doi: 10.2174/1568026619666190904163524
52Nanoparticles: Properties and Applications in Cancer Immunotherapy. 2019;25:1962 doi: 10.2174/1381612825666190708214240
53The Intriguing History of Cancer Immunotherapy. 2019;10: doi: 10.3389/fimmu.2019.02965